VNDA - Vanda Pharmaceutical...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $11.59 | Open | $11.66 |
| Volume | 283.1K | Market Cap | 632.24M |
| Yield | Last Dividend |
| Vanda Pharmaceuticals (VNDA) Meets Q1 Ea... | 05/06/20 |
| Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to... | |
| This company gets FDA green light to pro... | 04/21/20 |
| Vanda Pharmaceuticals CEO Dr. Mihael Polymeropoulos joins Yahoo Finance's Seana Smith on what's next for the company's potential coronavirus treatment... | |
| Vanda Begins Enrollment in Study for Sev... | 04/16/20 |
| Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory... | |
| The Daily Biotech Pulse: GenMark Diagnos... | 03/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) ... | |
| The Daily Biotech Pulse: Gilead Kicks Of... | 02/27/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs o... | |
| Vanda -4.1% amid profit miss, EPIONE stu... | 02/25/20 |
| Vanda Pharmaceuticals (NASDAQ:VNDA) is 4.1% lower after hours, following a miss on Q4 profits alongside news that its Phase III EPIONE clinical trial ... | |
| Vanda Reports results from the EPIONE st... | 02/25/20 |
| WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced results from a Phase III clinical trial (EP... | |
| Vanda Pharmaceuticals EPS misses by $0.0... | 02/25/20 |
| Vanda Pharmaceuticals (NASDAQ:VNDA): Q4 GAAP EPS of $0.08 misses by $0.03. Revenue of $60.9M (+14.8% Y/Y) beats by $1.32M. Shares +0.4%. Press Release | |
| The Daily Biotech Pulse: Moderna Ships C... | 02/25/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) ... | |
| Vanda comes up short in lawsuit with FDA... | 02/01/20 |
| Vanda Pharmaceuticals (NASDAQ:VNDA) is "determining the appropriate next steps" after the U.S. District Court for the District of Columbia ruled in fa... | |
| Vanda Pharmaceuticals (VNDA) Q3 2019 Ear... | 11/07/19 |
| VNDA earnings call for the period ending September 30, 2019. | |
| Vanda Pharmaceuticals : Initial filing b... | 10/28/19 |
| SEC Form 3 ??? | October 29, 2019 | |
| FDA fights Vanda court bid to avoid anim... | 10/08/19 |
| The U.S. Food and Drug Administration on Tuesday urged a federal judge to reject Vanda Pharmaceuticals Inc's challenge to its decision to require the ... | |
| Attention Biotech Investors: Mark Your C... | 08/28/19 |
| FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda Pharmaceuticals Inc. (NASD... | |
| Vanda Receives CRL From FDA for sNDA of ... | 08/20/19 |
| Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder. | |
| FDA Issues Complete Response For Vanda's... | 08/19/19 |
| Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) received a negative FDA verdict on its drug Hetlioz, the company said Monday. What Happened Vanda said Mond... | |
| Biotech Stock On The Radar: Is Vanda A B... | 08/13/19 |
| Small-cap biopharma Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) has withstood the market-wide sell-off witnessed in early August, thanks to the second-... | |
| The Week Ahead In Biotech: Vanda Awaits ... | 08/11/19 |
| Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data i... | |
| Why Vanda (VNDA) Might be Well Poised fo... | 08/08/19 |
| Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. | |
| Vanda Pharmaceuticals (VNDA) Surpasses Q... | 07/31/19 |
| Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues t... | |
| Attention Biotech Investors: Mark Your C... | 07/31/19 |
| Though light in terms of PDUFA events, July yielded mostly positive results. Quiet a few approvals came through, including Eli Lilly And Co (NYSE: LLY... | |
| Analysts Estimate Vanda Pharmaceuticals ... | 07/24/19 |
| Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the... | |
| Humane Society backs Vanda's animal drug... | 07/18/19 |
| The Humane Society of the United States is backing Vanda Pharmaceuticals Inc's fight against a U.S. Food and Drug Administration requirement that it c... | |
| The Daily Biotech Pulse: Nuvectra Files ... | 06/12/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) ... | |
| Should Investors Worry Over a Sluggish F... | 05/09/19 |
| Revenue from the company's two drug products decreased 10% from the fourth quarter of 2018. | |
| Vanda Pharmaceuticals (VNDA) Q1 2019 Ear... | 05/02/19 |
| VNDA earnings call for the period ending March 31, 2019. | |
| Vanda Pharmaceuticals Inc. (VNDA) CEO Mi... | 05/01/19 |
| Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2019 Results Earnings Conference Call May 01, 2019, 4:30 am ET Company Participants Jim Kelly - Executive ... | |
| Vanda Pharmaceuticals (VNDA) Q1 Earnings... | 05/01/19 |
| Vanda (VNDA) delivered earnings and revenue surprises of 500.00% and -7.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues... | |
| Vanda Pharmaceuticals misses by $0.01, m... | 05/01/19 |
| No summary available. | |
| Vanda Pharmaceuticals Q1 2019 Earnings P... | 04/30/19 |
| No summary available. | |
| Hold rating | 06/09/20 |
| Citigroup downgrades from Buy to Neutral rating and announces Price Target of $14.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swing for the fences | Gino Baldassano | 73.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
